Evidence map›Paper›PMID 26889976›Full record

ArticleBritish journal of cancer2016

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.

Steven C Kao, Michaela B Kirschner, Wendy A Cooper, Thang Tran, Sjaak Burgers, Casey Wright, Tiny Korse, Daan van den Broek, James Edelman, Michael Vallely and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Identification of Overexpressed Genes in Malignant Pleural Mesothelioma.International journal of molecular sciences · 2021
    Article
  8. Review
  9. Circulating biomarkers in malignant pleural mesothelioma.Exploration of targeted anti-tumor therapy · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Steven C KaoAsbestos Diseases Research Institute, PO Box 3628, Rhodes, Sydney, NSW2139, Australia.
Michaela B KirschnerAsbestos Diseases Research Institute, PO Box 3628, Rhodes, Sydney, NSW2139, Australia.
Wendy A CooperSydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Thang TranDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Sjaak BurgersDivision of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Casey WrightAsbestos Diseases Research Institute, PO Box 3628, Rhodes, Sydney, NSW2139, Australia.
Tiny KorseDivision of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Daan van den BroekDivision of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
James EdelmanDepartment of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Michael VallelySydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Brian McCaughanSydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Nick PavlakisSydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Stephen ClarkeSydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Mark P MolloyAustralian Proteome Analysis Facility, Macquarie University, Sydney, NSW 2109, Australia.
Nico van ZandwijkAsbestos Diseases Research Institute, PO Box 3628, Rhodes, Sydney, NSW2139, Australia.
Glen ReidAsbestos Diseases Research Institute, PO Box 3628, Rhodes, Sydney, NSW2139, Australia.
University of Sydney · AUThe Netherlands Cancer Institute · NLAsbestos Diseases Research Institute · AURoyal North Shore Hospital · AURoyal Prince Alfred Hospital · AUMacquarie University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to identify prognostic blood biomarkers using proteomics-based approaches in malignant pleural mesothelioma (MPM).

methodsPlasma samples from 12 MPM patients were used for exploratory mass spectrometry and ELISA analyses. The significance of secreted protein acidic and rich in cysteine (SPARC) was examined in sera from a Dutch series (n=97). To determine the source of the circulating SPARC, we investigated SPARC expression in MPM tumours and healthy controls, as well as the expression and secretion from cell lines and xenografts.

resultsSecreted protein acidic and rich in cysteine was identified as a putative prognostic marker in plasma. Validation in the Dutch series showed that the median survival was higher in patients with low SPARC compared with those with high SPARC (19.0 vs 8.8 months; P=0.01). In multivariate analyses, serum SPARC remained as an independent predictor (HR 1.55; P=0.05). In MPM tumour samples, SPARC was present in the tumour cells and stromal fibroblasts. Cellular SPARC expression was higher in 5 out of 7 cell lines compared with two immortalized mesothelial lines. Neither cell lines nor xenograft tumours secreted detectable SPARC.

conclusionsLow circulating SPARC was associated with favourable prognosis. Secreted protein acidic and rich in cysteine was present in both tumour cells and stromal fibroblasts; and our in vitro and in vivo experiments suggest that stromal fibroblasts are a potential source of circulating SPARC.

Indexed as

AnimalsBiomarkers, TumorCell Line, TumorEnzyme-Linked Immunosorbent AssayFemaleHumansImmunohistochemistryLung NeoplasmsMaleMass SpectrometryMesotheliomaMesothelioma, MalignantMiceMiddle AgedMultivariate AnalysisNeoplasm TransplantationBiomarkers, TumorOsteonectinSPARC protein, human

Identifiers

PMID26889976
PMCPMC4782201
OpenAlexW2280072156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.